Artal Group’s Clovis Oncology, Inc. CLVS Stock Holding History

Artal Group’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-500,000	Closed	-$3.38M	–	154
2020 Q2	$3.38M	Hold	500,000	–	–	0.09%	116
2020 Q1	$3.18M	Sell	500,000 -250,000	-33%	-$2.01M	0.13%	89
2019 Q4	$7.82M	Buy	+750,000	New	+$5.45M	0.3%	57
2019 Q1	–	Sell	-200,000	Closed	-$3.59M	–	120
2018 Q4	$3.59M	Buy	+200,000	New	+$4.09M	0.13%	77
2018 Q3	–	Sell	-100,000	Closed	-$4.55M	–	119
2018 Q2	$4.55M	Sell	100,000 -150,000	-60%	-$7.3M	0.1%	71
2018 Q1	$13.2M	Buy	250,000 +100,000	+67%	+$5.83M	0.17%	41
2017 Q4	$10.2M	Buy	+150,000	New	+$10.5M	0.15%	46

Other funds holding CLVS

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Artal Group's CLVS Position: Q2 2020 in Review

Artal Group sold out of Clovis Oncology, Inc. (CLVS) in Q2 2020, closing a stake of 1,000,000 shares — an estimated $7.57M sold.

Artal Group first reported a position in CLVS in Q4 2016 and held it in 7 quarters. The position peaked at $10.4M in Q4 2019. 158 funds tracked by Wall St. Rank hold CLVS as of Q2 2020.

Artal Group reported no remaining Clovis Oncology, Inc. position as of Q2 2020 after selling out during the quarter.
Artal Group sold 1,000,000 Clovis Oncology, Inc. shares in Q2 2020, an estimated $7.57M.
Artal Group first reported a position in Clovis Oncology, Inc. in Q4 2016 and held it in 7 quarters.
Artal Group's Clovis Oncology, Inc. position peaked at $10.4M in Q4 2019.
158 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2020.

Based on Artal Group's 13F filing for Q2 2020, filed 14 Aug 2020.